The efficacy of the traditional Chinese medicine Jia Wei Niu Bang Zi granule combined with methotrexate in treating active rheumatoid arthritis: A multicenter, randomized, double-blinded controlled clinical trial

Yi-Ru Wang, Li Liu, Xiao-Yun Wang, Qiong Wang, Min Yao, Xue-Jun Cui, Jian-Chun Mao, Jian Liu, Xiao-Hua Gu, Yong-Li Chen, Xiang Yu, Qi Shi, Qian-Qian Liang, Yong-Jun Wang, Yi-Ru Wang, Li Liu, Xiao-Yun Wang, Qiong Wang, Min Yao, Xue-Jun Cui, Jian-Chun Mao, Jian Liu, Xiao-Hua Gu, Yong-Li Chen, Xiang Yu, Qi Shi, Qian-Qian Liang, Yong-Jun Wang

Abstract

Background: Rheumatoid arthritis (RA) is a chronic systemic and autoimmune inflammatory disease ending with the destruction of joints. Current therapies can relieve RA symptoms, but some also bring severe adverse events. Therefore, an effective and safe therapeutic strategy remains to be created to benefit patients with RA by large. Jia Wei Niu Bang Zi granule (NBZG) consisting of RA-fighting Chinese herbals has been used in Longhua Hospital in the last several decades. NBZG has potential therapeutic effect on RA, which should be evaluated by larger sample clinical trial.

Methods: A multicenter, randomized, double-blind, placebo-controlled clinical trials will be conducted to determine the efficiency of NBZG in pain relief and joint protection. A total of 120 patients with active RA will be enrolled, and treated with NBZG or placebo for 12 weeks. The primary outcome measurements include rate of American College of Rheumatology (ACR) 50 at 12 weeks' treatment. The 2nd outcome measurements include rate change of ACR20, ACR70, the disease activity score (DAS) 28, 36-item Short-Form Health Survey Questionnaire, Health Assessment Questionnaire - Disability Index, score changes of Patient Assessment of Arthritis Pain, Patient Global Assessment of Arthritis, and the Athens insomnia scale at the same time points.

Discussion: Although NBZG has shown efficacy in treating RA in Longhua Hospital for decades, the universality of this efficacy needs evaluated. The results of this trial will provide a convincing evidence about NBZG's efficacy in treating active RA in a large population.

Trial registration: ClinicalTrials.gov ID: NCT03173040 (registered on May 30, 2017).

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Project overview. RA = rheumatoid arthritis, NBZG = Jia Wei Niu Bang Zi granule.

References

    1. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907–16.
    1. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001;27:269–81.
    1. Gabriel SE, Crowson CS, O’Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955–1985. Arthritis Rheum 1999;42:415–20.
    1. Zhang GG, Lee W, Bausell B, et al. Variability in the traditional Chinese medicine (TCM) diagnoses and herbal prescriptions provided by three TCM practitioners for 40 patients with rheumatoid arthritis. J Altern Complement Med 2005;11:415–21.
    1. Lu C, Zha Q, Chang A, et al. Pattern differentiation in traditional Chinese medicine can help define specific indications for biomedical therapy in the treatment of rheumatoid arthritis. J Altern Complement Med 2009;15:1021–5.
    1. Li JL, Chen Y, Zhang L, et al. Jia-Wei-Niu-Bang-Zi-Tang promoted draining function of lymphatic vessels to prevent and cure rheumatoid arthritis. Chin J Integr Traditional Western Med 2017;37:710–5.
    1. Fayers P. Approaches to sample size estimation in the design of clinical trials--a review. By A. Donner, Statistics in Medicine, 3, 199-214 (1984). Stat Med 1993;12:1643.
    1. Cader MZ, Filer A, Hazlehurst J, et al. Performance of the 2010 ACR/EULAR criteria for rheumatoid arthritis: comparison with 1987 ACR criteria in a very early synovitis cohort. Ann Rheum Dis 2011;70:949–55.
    1. Gardiner PV, Bell AL, Taggart AJ, et al. A potential pitfall in the use of the disease activity score (DAS28) as the main response criterion in treatment guidelines for patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:506–7.
    1. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.
    1. Chung CP, Thompson JL, Koch GG, et al. Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities. Ann Rheum Dis 2006;65:1602–7.
    1. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993;36:729–40.
    1. Felson DT, Anderson JJ, Lange ML, et al. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 1998;41:1564–70.
    1. Lacroix BD, Karlsson MO, Friberg LE. Simultaneous exposure-response modeling of ACR20, ACR50, and ACR70 improvement scores in rheumatoid arthritis patients treated with Certolizumab Pegol. CPT Pharmacometrics Syst Pharmacol 2014;3:e143.
    1. Dougados M, Schmidely N, Le Bars M, et al. Evaluation of different methods used to assess disease activity in rheumatoid arthritis: analyses of abatacept clinical trial data. Ann Rheum Dis 2009;68:484–9.
    1. van der Heijde DM, van ’t Hof M, van Riel PL, et al. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579–81.
    1. Landewe R, van der Heijde D, van der Linden S, et al. Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. Ann Rheum Dis 2006;65:637–41.
    1. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 2003;30:167–78.
    1. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes 2003;1:20.
    1. Loppenthin K, Esbensen BA, Jennum P, et al. Sleep quality and correlates of poor sleep in patients with rheumatoid arthritis. Clin Rheumatol 2015;34:2029–39.
    1. Sariyildiz MA, Batmaz I, Bozkurt M, et al. Sleep quality in rheumatoid arthritis: relationship between the disease severity, depression, functional status and the quality of life. J Clin Med Res 2014;6:44–52.
    1. Westhovens R, Van der Elst K, Matthys A, et al. Sleep problems in patients with rheumatoid arthritis. J Rheumatol 2014;41:31–40.
    1. Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res 2000;48:555–60.
    1. Soldatos CR, Dikeos DG, Paparrigopoulos TJ. The diagnostic validity of the Athens insomnia scale. J Psychosom Res 2003;55:263–7.
    1. Aaronson NK, Muller M, Cohen PD, et al. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol 1998;51:1055–68.
    1. Ruta D, Garratt A, Abdalla M, et al. The SF 36 health survey questionnaire. A valid measure of health status. BMJ 1993;307:448–9.
    1. Linde L, Sorensen J, Ostergaard M, et al. Health-related quality of life: validity, reliability, and responsiveness of SF-36, 15D, EQ-5D [corrected] RAQoL, and HAQ in patients with rheumatoid arthritis. J Rheumatol 2008;35:1528–37.
    1. Matcham F, Scott IC, Rayner L, et al. The impact of rheumatoid arthritis on quality-of-life assessed using the SF-36: a systematic review and meta-analysis. Semin Arthritis Rheum 2014;44:123–30.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する